Publications

Detailed Information

Effects of neonatal MK-801 treatment on p70S6K-S6/eIF4B signal pathways and protein translation in the frontal cortex of the developing rat brain

DC Field Value Language
dc.contributor.authorKim, Se Hyun-
dc.contributor.authorPark, Hong Geun-
dc.contributor.authorKim, Han Soo-
dc.contributor.authorAhn, Yong Min-
dc.contributor.authorKim, Yong Sik-
dc.date.accessioned2012-07-03T04:29:22Z-
dc.date.available2012-07-03T04:29:22Z-
dc.date.issued2010-10-
dc.identifier.citationINTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY; Vol.13 9; 1233-1246ko_KR
dc.identifier.issn1461-1457-
dc.identifier.urihttps://hdl.handle.net/10371/78211-
dc.description.abstractSystemic injections of MK-801, a selective NMDAR antagonist, into neonatal rats induces long-term neurochemical and behavioural changes. It has been suggested that these changes form the neurodevelopmental basis for schizophrenia-like behaviour in rats. In this study, 7-d-old rats were treated with MK-801, and their frontal cortices were examined to investigate the effects on p70S6K-S6 signal pathway and on protein translation, which play crucial roles in the neurodevelopmental process. MK-801, in doses of 0.5 and 1.0 mg/kg, induced a decrease in phosphorylation of p70S6K and its substrates, S6 and eIF4B, in the first 8 h, and no change at 24 and 48 h. These effects were more prominent after two injections of MK-801 than one. Decreased S6 phosphorylation by MK-801 was evident in the prefrontal, cingulate, and insular cortex. In two representative upstream p70S6K-S6 pathways related to ERK1/2 and Akt, changes in ERK1/2-p90RSK phosphorylation were accompanied by changes of p70S6K-S6. Although two MK-801 injections induced a dose-dependent decrease in phosphorylation of Akt and mTOR at 4 and 8 h, a single injection did not produce a significant effect. Protein synthesis rate, measured by [(3)H] leucine incorporation in frontal cortical tissue, was reduced until 24 h after two MK-801 (1.0 mg/kg) injections. In summary, this study found that neonatal MK-801 treatment induced dysregulation in the p70S6K-S6/eIF4B pathway and protein translation in the frontal cortex of the developing rat brain, which may suggest an important role of protein translation machinery in the MK-801 neurodevelopmental animal model of schizophrenia.ko_KR
dc.description.sponsorshipThis research was supported by a grant (no. A060477)
from the Korea Health 21 R&D Project, Ministry of
Health & Welfare, and by a grant (no. M103KV010013-
07K2201-01310) from the Brain Research Centre of the
21st Century Frontier Research Programme funded
by the Ministry of Science and Technology, Republic
of Korea.
ko_KR
dc.language.isoenko_KR
dc.publisherCAMBRIDGE UNIV PRESSko_KR
dc.subjectNeurodevelopmentko_KR
dc.subjectN-methyl-D-aspartate receptorko_KR
dc.subjectschizophreniako_KR
dc.subjectsmall ribosomal protein 6ko_KR
dc.subjectprotein synthesisko_KR
dc.titleEffects of neonatal MK-801 treatment on p70S6K-S6/eIF4B signal pathways and protein translation in the frontal cortex of the developing rat brainko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor김세현-
dc.contributor.AlternativeAuthor박홍근-
dc.contributor.AlternativeAuthor김한수-
dc.contributor.AlternativeAuthor안용민-
dc.contributor.AlternativeAuthor김용식-
dc.identifier.doi10.1017/S1461145709991192-
dc.citation.journaltitleINTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY-
dc.description.citedreferenceUehara T, 2009, PSYCHOPHARMACOLOGY, V206, P623, DOI 10.1007/s00213-009-1527-2-
dc.description.citedreferenceFatemi SH, 2009, SCHIZOPHRENIA BULL, V35, P528, DOI 10.1093/schbul/sbn187-
dc.description.citedreferenceCopp J, 2009, CANCER RES, V69, P1821, DOI 10.1158/0008-5472.CAN-08-3014-
dc.description.citedreferenceCosta-Mattioli M, 2009, NEURON, V61, P10, DOI 10.1016/j.neuron.2008.10.055-
dc.description.citedreferenceWang CZ, 2008, NEUROPSYCHOPHARMACOL, V33, P2442, DOI 10.1038/sj.npp.1301647-
dc.description.citedreferenceXia Y, 2008, J PHARMACOL EXP THER, V326, P838, DOI 10.1124/jpet.107.133272-
dc.description.citedreferenceLei G, 2008, NEUROPSYCHOPHARMACOL, V33, P1343, DOI 10.1038/sj.npp.1301511-
dc.description.citedreferenceYoon SC, 2008, NEUROSCI LETT, V434, P23, DOI 10.1016/j.neulet.2008.01.020-
dc.description.citedreferenceAnastasio NC, 2008, J NEUROCHEM, V104, P1210, DOI 10.1111/j.1471-4159.2007.05047.x-
dc.description.citedreferenceMeyuhas O, 2008, INT REV CEL MOL BIO, V268, P1, DOI 10.1016/S1937-6448(08)00801-0-
dc.description.citedreferenceSutton MA, 2007, NEURON, V55, P648, DOI 10.1016/j.neuron.2007.07.030-
dc.description.citedreferenceBessard A, 2007, J CELL PHYSIOL, V212, P526, DOI 10.1002/jcp.21049-
dc.description.citedreferenceAbekawa T, 2007, PSYCHOPHARMACOLOGY, V192, P303, DOI 10.1007/s00213-007-0729-8-
dc.description.citedreferenceSeo MS, 2007, INT J NEUROPSYCHOPH, V10, P359, DOI 10.1017/S1461145706006869-
dc.description.citedreferenceRoux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200-
dc.description.citedreferenceProud CG, 2007, BIOCHEM J, V403, P217, DOI 10.1042/BJ20070024-
dc.description.citedreferenceDU BOIS TM, 2007, BRAIN RES REV, V53, P260-
dc.description.citedreferenceJaworski J, 2006, MOL NEUROBIOL, V34, P205, DOI 10.1385/MN:34:3:205-
dc.description.citedreferenceGong RM, 2006, NEUROREPORT, V17, P1575, DOI 10.1097/01.wnr.0000234742.42818.ff-
dc.description.citedreferenceAhn YM, 2006, INT J NEUROPSYCHOPH, V9, P451, DOI 10.1017/S1461145705005882-
dc.description.citedreferenceGong R, 2006, J BIOL CHEM, V281, P18802, DOI 10.1074/jbc.M512524200-
dc.description.citedreferenceRuvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003-
dc.description.citedreferenceTome CML, 2006, NEUROSCIENCE, V141, P1351, DOI 10.1016/j.neuroscience.2006.05.019-
dc.description.citedreferenceAhn YM, 2005, INT J NEUROPSYCHOPH, V8, P607, DOI 10.1017/S1461145705005353-
dc.description.citedreferenceRuggero D, 2005, ONCOGENE, V24, P7426, DOI 10.1038/sj.onc.1209098-
dc.description.citedreferenceChiang GG, 2005, J BIOL CHEM, V280, P25485, DOI 10.1074/jbc.M501707200-
dc.description.citedreferenceWedzony K, 2005, J PHYSIOL PHARMACOL, V56, P205-
dc.description.citedreferenceStefani MR, 2005, BIOL PSYCHIAT, V57, P433, DOI 10.1016/j.biopsych.2004.11.031-
dc.description.citedreferenceParsa AT, 2004, TRENDS MOL MED, V10, P607, DOI 10.1016/j.molmed.2004.10.009-
dc.description.citedreferenceMothe-Satney I, 2004, J BIOL CHEM, V279, P42628, DOI 10.1074/jbc.M405173200-
dc.description.citedreferenceHansen HH, 2004, NEUROBIOL DIS, V16, P440, DOI 10.1016/j.nbd.2004.03.013-
dc.description.citedreferenceJackson ME, 2004, P NATL ACAD SCI USA, V101, P8467, DOI 10.1073/pnas.0308455101-
dc.description.citedreferenceRaught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193-
dc.description.citedreferencePende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004-
dc.description.citedreferenceDzietko M, 2004, NEUROBIOL DIS, V15, P177, DOI 10.1016/j.nbd.2003.10.006-
dc.description.citedreferenceKELLEHER RJ III, 2004, NEURON, V44, P59-
dc.description.citedreferenceHarris LW, 2003, EUR J NEUROSCI, V18, P1706, DOI 10.1046/j.1460-9568.2003.02902.x-
dc.description.citedreferenceWiley JL, 2003, PROG NEURO-PSYCHOPH, V27, P867, DOI 10.1016/S0278-5846(03)00146-5-
dc.description.citedreferenceTakahata R, 2003, NEUROPSYCHOPHARMACOL, V28, P1117, DOI 10.1038/sj.npp.1300127-
dc.description.citedreferenceWang XM, 2003, MOL CELL BIOL, V23, P1546, DOI 10.1128/MCB.23.5.1546-1557.2003-
dc.description.citedreferenceSircar R, 2003, PHARMACOL BIOCHEM BE, V74, P943, DOI 10.1016/S0091-3057(03)00025-X-
dc.description.citedreferenceLorrain DS, 2003, NEUROSCIENCE, V117, P697, DOI 10.1016/S0306-4522(02)00652-8-
dc.description.citedreferenceAndersen SL, 2003, NEUROSCI BIOBEHAV R, V27, P3, DOI 10.1016/S0149-7634(03)00005-8-
dc.description.citedreferenceRitter LM, 2002, DEV BRAIN RES, V139, P227, DOI 10.1016/S0165-3806(02)00572-2-
dc.description.citedreferenceSutton G, 2002, J NEUROCHEM, V82, P1097, DOI 10.1046/j.1471-4159.2002.01031.x-
dc.description.citedreferenceLehman JA, 2002, BIOCHEM BIOPH RES CO, V293, P463, DOI 10.1016/S0006-291X(02)00238-3-
dc.description.citedreferenceChandler LJ, 2001, J BIOL CHEM, V276, P2627, DOI 10.1074/jbc.M003390200-
dc.description.citedreferenceClancy B, 2001, NEUROSCIENCE, V105, P7, DOI 10.1016/S0306-4522(01)00171-3-
dc.description.citedreferenceGreene R, 2001, HIPPOCAMPUS, V11, P569, DOI 10.1002/hipo.1072-
dc.description.citedreferenceROGERS GW JR, 2001, J BIOL CHEM, V276, P30914-
dc.description.citedreferenceSekulic A, 2000, CANCER RES, V60, P3504-
dc.description.citedreferenceContestabile A, 2000, BRAIN RES REV, V32, P476, DOI 10.1016/S0165-0173(00)00018-7-
dc.description.citedreferencePeterson RT, 2000, J BIOL CHEM, V275, P7416, DOI 10.1074/jbc.275.10.7416-
dc.description.citedreferenceSircar R, 2000, INT J DEV NEUROSCI, V18, P121, DOI 10.1016/S0736-5748(99)00069-6-
dc.description.citedreferenceDufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683-
dc.description.citedreferenceJentsch JD, 1999, NEUROPSYCHOPHARMACOL, V20, P201, DOI 10.1016/S0893-133X(98)00060-8-
dc.description.citedreferenceIkonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70-
dc.description.citedreferenceNicoll RA, 1999, ANN NY ACAD SCI, V868, P515, DOI 10.1111/j.1749-6632.1999.tb11320.x-
dc.description.citedreferencePaxinos G, 1998, RAT BRAIN STEREOTACT-
dc.description.citedreferenceSircar R, 1998, ANN NY ACAD SCI, V844, P303, DOI 10.1111/j.1749-6632.1998.tb08244.x-
dc.description.citedreferenceBreier A, 1997, AM J PSYCHIAT, V154, P805-
dc.description.citedreferenceMoghaddam B, 1997, J NEUROSCI, V17, P2921-
dc.description.citedreferenceOLNEY JW, 1995, ARCH GEN PSYCHIAT, V52, P998-
dc.description.citedreferencePEARSON RB, 1995, EMBO J, V14, P5279-
dc.description.citedreferenceSUN Y, 1995, AM J PHYSIOL-REG I, V268, pR549-
dc.description.citedreferenceBURDA J, 1994, BIOCHEM J, V302, P335-
dc.description.citedreferenceKOMURO H, 1993, SCIENCE, V260, P95, DOI 10.1126/science.8096653-
dc.description.citedreferenceBRACHA HS, 1992, AM J PSYCHIAT, V149, P1355-
dc.description.citedreferenceMULLEN RJ, 1992, DEVELOPMENT, V116, P201-
dc.description.citedreferenceNYGARD O, 1990, EUR J BIOCHEM, V191, P1, DOI 10.1111/j.1432-1033.1990.tb19087.x-
dc.description.citedreferenceMEDNICK SA, 1988, ARCH GEN PSYCHIAT, V45, P189-
dc.description.citedreferenceKUBISTA M, 1987, BIOCHEMISTRY-US, V26, P4545, DOI 10.1021/bi00388a057-
dc.description.citedreferenceCOSGROVE JW, 1986, NEUROCHEM RES, V11, P1289, DOI 10.1007/BF00966123-
dc.description.citedreferenceFANDO JL, 1980, NEUROCHEM RES, V5, P197, DOI 10.1007/BF00964332-
dc.description.citedreferenceFANDO JL, 1980, NEUROCHEM RES, V5, P373, DOI 10.1007/BF00964226-
dc.description.tc1-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share